Entera Bio (ENTX) Short-term Investments (2017 - 2025)
Entera Bio's (ENTX) quarterly Short-term Investments came in at $7.8 million in Q4 2025, up 800.93% on a QoQ basis from $863000.0 in Q2 2021.
Entera Bio (ENTX) Short-term Investments (2017 - 2025) Analysis & Trends
Entera Bio (ENTX) has 6 years of Short-term Investments data on file, last reported at $7.8 million in Q4 2025.
- Quarterly Short-term Investments changed N/A year-over-year to $7.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.8 million (changed N/A YoY) and the FY2025 annual result came in at $7.8 million, changed N/A from the prior year.
- Short-term Investments advanced to $7.8 million in Q4 2025, from $863000.0 in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $7.8 million in Q4 2025 to a low of $863000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.78 Mn |
| Jun 30, 2021 | 863,000.00 |
| Dec 31, 2020 | 261,000.00 |
| Jun 30, 2020 | 677,000.00 |
| Dec 31, 2019 | 173,000.00 |
| Dec 31, 2018 | 220,000.00 |
| Dec 31, 2017 | 671,000.00 |